The impact of missing data on clinical trials: a re-analysis of a placebo controlled trial of Hypericum perforatum (St Johns wort) and sertraline in major depressive disorder
Anneke C Grobler, Glenda Matthews, Geert Molenberghs
Psychopharmacology | SPRINGER | Published : 2014
Awarded by NIMH
Awarded by IAP of the Belgian Government (Belgian Science Policy)
Data used in the preparation of this article were obtained from the limited access datasets (version 4.1) distributed from the NIH-supported "A Placebo-Controlled Clinical Trial of a Standardized Extract of H. perforatum in Major Depressive Disorder" (Hypericum). This is a multisite, clinical trial of persons with depression comparing the effectiveness of randomly assigned medication treatment. The purpose of this trial is to study the acute efficacy and safety of a standardized extract of the herb H. perforatum (St. John's wort) in the treatment of patients with major depression. The study was supported by NIMH contract # N01MH70007 to the Duke University Medical Center. The ClinicalTrials.gov identifier is NCT00005013. This manuscript reflects the views of the authors and may not reflect the opinions or views of the Hypericum Study Investigators or the NIH. Anneke Grobler had full access to the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.Geert Molenberghs gratefully acknowledges financial support from the IAP research Network P7/06 of the Belgian Government (Belgian Science Policy).